Tag Archives: drug development

Beyond the ABCs of ADCs

Antibody

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice

oncology

Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Perspective on Market Valuation for Biotech Drug Developers

Graph

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

IP Position Critical to Biotech Investment

A great article from Genetic Engineering and Biotechnology News written by Lisa Haile reviewing the Myriad case and its implications for future medical advances. Interesting Quotes: “While it is unfortunate, I have seen quite a few technologies over the years that would be of potential great benefit to patients, but the intellectual property was simply not there to support protecting the product from fast followers in the market place,” explains Robert More, a general partner Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

How Profitable is the Biotech Drug Development Sector?

Q: How many public biotechnology companies focused on pursuing drug development are profitable? A: Less than 10% Of 225 public biotech companies in the drug development business, only 17 are profitable (7.5%) based on 2009 Net Income. The profitable companies tend to be those with three or more products: Only 1.3% have 1 product AND are profitable (3 of 225) Only 0.9% have 2 products AND make a profit (2 of 225) Only 5.3% have Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,